转移性去势抵抗性前列腺癌（mCRPC）的现有及新兴疗法
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
作者信息
Henríquez Iván, Roach Mack, Morgan Todd M, Bossi Alberto, Gómez Junior A, Abuchaibe Oscar, Couñago Felipe
机构信息
Department of Radiation Oncology, Hospital Universitario Sant Joan, 43204 Reus, Spain.
UCSF Helen Diller Family Comprehensive Cancer Center, Department of Radiation Oncology, San Francisco, CA 94143, USA.
出版信息
Biomedicines. 2021 Sep 17;9(9):1247. doi: 10.3390/biomedicines9091247.
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous wide range of molecular tumor behavior and a high risk of progression. Early detection and treatment are therefore crucial in these patients. Treatment has improved drastically in recent years and many novel therapeutic agents are currently under investigation. However, due to the rapidly changing therapeutic landscape in mCRPC, it is difficult for clinicians to keep up to date with the latest innovations in this area. In the present narrative review, we discuss the current and emerging therapies for mCRPC as well as the clinical and molecular factors that can help predict which patients are most likely to benefit from these novel agents.
摘要
转移性去势抵抗性前列腺癌（mCRPC）包含广泛的异质性分子肿瘤行为和高进展风险。因此，早期检测和治疗对这些患者至关重要。近年来治疗有了显著改善，目前许多新型治疗药物正在研究中。然而，由于mCRPC的治疗格局迅速变化，临床医生很难跟上该领域的最新创新。在本叙述性综述中，我们讨论了mCRPC的当前和新兴疗法，以及有助于预测哪些患者最可能从这些新型药物中获益的临床和分子因素。
相似文献
1
Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Biomedicines. 2021 Sep 17;9(9):1247. doi: 10.3390/biomedicines9091247.
2
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16.
3
Sequencing current therapies in the treatment of metastatic prostate cancer.
Cancer Treat Rev. 2015 Apr;41(4):332-40. doi: 10.1016/j.ctrv.2015.02.010. Epub 2015 Mar 4.
4
Current therapeutic options in metastatic castration-resistant prostate cancer.
Semin Oncol. 2018 Oct;45(5-6):303-315. doi: 10.1053/j.seminoncol.2018.10.001. Epub 2018 Oct 30.
5
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.
6
Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo.
Cancer Drug Resist. 2022 Jun 22;5(3):667-690. doi: 10.20517/cdr.2022.15. eCollection 2022.
7
A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Pharmacotherapy. 2017 Nov;37(11):1406-1414. doi: 10.1002/phar.2027.
8
Recent Advances in DNA Repair Pathway and Its Application in Personalized Care of Metastatic Castration-Resistant Prostate Cancer (mCRPC).
Methods Mol Biol. 2020;2204:75-89. doi: 10.1007/978-1-0716-0904-0_7.
9
Taxane-based Combination Therapies for Metastatic Prostate Cancer.
Eur Urol Focus. 2019 May;5(3):369-380. doi: 10.1016/j.euf.2017.11.009. Epub 2017 Dec 21.
10
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18.
引用本文的文献
1
Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate Cancer.
Adv Ther. 2025 Jun 17. doi: 10.1007/s12325-025-03270-z.
2
A Bayesian Network Meta-analysis of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer in First- and Subsequent Lines.
Target Oncol. 2025 Jun 10. doi: 10.1007/s11523-025-01148-2.
3
(-)-Oleuropein as a Novel Metastatic Castration-Resistant Prostate Cancer Progression and Recurrence Suppressor via Targeting PCSK9-LDLR Axis.
Nutrients. 2025 Apr 25;17(9):1445. doi: 10.3390/nu17091445.
4
Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugates: A Promising Approach for Metastatic Castration-Resistant Prostate Cancer.
Cells. 2025 Mar 30;14(7):513. doi: 10.3390/cells14070513.
5
DNA Repair Capacity and Clinicopathological Characteristics in Puerto Rican Hispanic/Latino Patients with Metastatic Castration-Resistant Prostate Cancer.
Cancers (Basel). 2025 Jan 16;17(2):279. doi: 10.3390/cancers17020279.
6
Identifying MTHFD1 and LGALS4 as Potential Therapeutic Targets in Prostate Cancer Through Multi-Omics Mendelian Randomization Analysis.
Biomedicines. 2025 Jan 13;13(1):185. doi: 10.3390/biomedicines13010185.
7
Real-world efficacy and safety of combined first-line treatment with PARP inhibitors and novel hormonal therapy in mCRPC patients with HRR gene mutations.
Front Genet. 2024 Dec 6;15:1505163. doi: 10.3389/fgene.2024.1505163. eCollection 2024.
8
Bone health management in endocrine-treated patients with prostate cancer: a summary of evidence.
BMC Urol. 2024 Dec 20;24(1):271. doi: 10.1186/s12894-024-01663-w.
9
Prognostic value of baseline alkaline phosphatase of 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
PLoS One. 2024 Dec 12;19(12):e0307826. doi: 10.1371/journal.pone.0307826. eCollection 2024.
10
A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer.
Cancer Immunol Res. 2025 Feb 3;13(2):258-272. doi: 10.1158/2326-6066.CIR-24-0273.
本文引用的文献
1
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10.
2
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
3
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.
4
Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease.
World J Clin Oncol. 2021 Jan 24;12(1):6-12. doi: 10.5306/wjco.v12.i1.6.
5
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
J Natl Compr Canc Netw. 2021 Feb 2;19(2):134-143. doi: 10.6004/jnccn.2021.0008.
6
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Prostate. 2020 Oct;80(14):1159-1176. doi: 10.1002/pros.24053. Epub 2020 Aug 11.
7
Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.
J Clin Oncol. 2020 Aug 20;38(24):2798-2811. doi: 10.1200/JCO.20.00046. Epub 2020 Jun 9.
8
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.
9
Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer.
Oncologist. 2020 Jul;25(7):e1042-e1050. doi: 10.1634/theoncologist.2019-0495. Epub 2020 Mar 19.
10
Colorectal cancer statistics, 2020.
CA Cancer J Clin. 2020 May;70(3):145-164. doi: 10.3322/caac.21601. Epub 2020 Mar 5.
Zotero 插件